Oral Ozempic and the Risks of Compounding Formulas

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!

In this episode, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, explore major updates in the evolving GLP-1 receptor agonist landscape, with a particular focus on oral semaglutide formulations, branding changes, and regulatory concerns surrounding compounded alternatives.

Key Episode Timestamps
00:00:01 Intro
00:00:25 Oral Wegovy and oral Ozempic
00:03:04 Why Rybelsus didn't work
00:05:33 The importance of administration
00:06:56 Compounding drugs - the Hims and Hers drama
00:07:56 The danger of unregulated compound drugs
00:11:50 Outro